Cryo‑Cell International, Inc. renewed its Foundation for the Accreditation of Cellular Therapy (FACT) accreditation for its cord blood collection, banking, and release operations on April 30 2026. The new certification, valid through April 3 2029, confirms that the company continues to meet the NetCord‑FACT standards, the most rigorous quality framework for cord blood banking worldwide.
The renewal reinforces Cryo‑Cell’s claim of having the longest independently validated quality track record among U.S. private cord blood banks. The company has held FACT accreditation continuously since 2014, a fact that underscores its long‑term commitment to the highest industry standards and positions it favorably for physician referrals and patient confidence.
Financially, Cryo‑Cell reported a net loss of $2.4 million for fiscal year 2025, compared with a net income of $402,000 in fiscal year 2024. In the first quarter of fiscal year 2026, revenue fell to $7.68 million from $7.97 million in the same quarter a year earlier, and net income dropped to $47,000 from $283,000. The loss in 2025 was largely driven by a $4.4 million impairment charge recorded in the fourth quarter of that year.
Co‑CEO David Portnoy said, "FACT accreditation is the standard used by the world's leading transplant centers for evaluating public cord blood banks. Earning and renewing this credential for private banking demonstrates that the Company operates at that same level of rigor." The statement highlights how the accreditation supports Cryo‑Cell’s positioning against public banks and signals to partners and patients that the company maintains the same level of quality.
While the accreditation renewal strengthens Cryo‑Cell’s credibility, the company continues to face financial headwinds. It has received a notice from NYSE American for not meeting continued listing standards due to a stockholders' deficit and recent net losses, and it is developing a plan to regain compliance. The accreditation, therefore, represents a key operational milestone that must be weighed against ongoing financial challenges when assessing the company’s long‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.